OpGen

OpGen Liabilities

The The Liabilities of OpGen (OPGN) as of Oct 23, 2026 is 6.20 M USD. In the previous year, The Liabilities was 2.48 M USD — a change of 149.73% (higher).

Liabilities

6.20 MUSD

YoY

149.73%

Last updated:

In 2025, OpGen's total liabilities amounted to 6.20 M USD, a 149.73% difference from the 2.48 M USD total liabilities in the previous year.

The OpGen Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
5.64 M USD
Jan 1, 2019
6.13 M USD
Jan 1, 2020
28.56 M USD
Jan 1, 2021
30.45 M USD
Jan 1, 2022
18.25 M USD
Jan 1, 2023
13.44 M USD
Jan 1, 2024
2.48 M USD
Jan 1, 2025
6.20 M USD
The OpGen Liabilities history
YEARLiabilitiesYoY
6.20 MUSD+149.73%
2.48 MUSD-81.54%
13.44 MUSD-26.35%
18.25 MUSD-40.05%
30.45 MUSD+6.62%
28.56 MUSD+366.02%
6.13 MUSD+8.63%
5.64 MUSD+8.10%
5.22 MUSD-10.27%
5.82 MUSD-7.26%
6.27 MUSD-41.50%
10.72 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing OpGen's Liabilities

OpGen's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating OpGen's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing OpGen's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

OpGen's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in OpGen’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about OpGen stock

The Liabilities of OpGen is 6.20 M USD in 2025.

The Liabilities of OpGen changed from 2.48 M USD to 6.20 M USD, representing a 149.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities OpGen since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's OpGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — OpGen

All Key Metrics — OpGen